CD274 and neoplasm: Tumors with P/LP fusions had lower rates of PD-L1+ expression compared to fusion-negative tumors (26.1 vs. 45.9%, p = 0.0619), which was consistent with a reduced rate of high tumor mutational burden (TMB-H, ≥10 mutations/Mb) (33.3 vs. 53.3%, p = 0.0258).